BriefTea
Every story in sixty words
Get the free app no ads · no paywallExplained in plain English
The story mentions 'sticky proteins' accumulating between brain cells. These are often amyloid beta proteins, which form plaques in the brains of people with Alzheimer's. Researchers believe these plaques disrupt brain cell function. Trontinemab is designed to target and remove these proteins, potentially delaying or stopping the disease's progression.
Stories that explain this
Surrey NHS trust joins trial of new Alzheimer's prevention drugRelated explainers
What is Alzheimer's? How do new drugs get approved? Why is prevention so important? Is 100g protein a lot? Why choose plant protein? What are complete proteins? What are protein powders for? What is whey protein?The full catalogue
Browse every card filed under S →We would like to count visits and see which links bring readers here. That means storing a random ID in your browser. No cookies, no ads, no profile. How it works.